Enveric Biosciences, Inc.
ENVB · XNASCIK 890821fmd_08ZRX5VKBF81DK5D9YC3S23METManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 36 | 49 | 43 | 40 | – | – | – | – | – | – |
| Cost of revenue | 29 | 38 | 34 | 32 | – | – | – | – | – | – |
| Net interest income | – | – | – | – | – | – | (0) | 0 | 0 | (0) |
| Gross profit | 7 | 10 | 9 | 8 | – | – | – | – | – | – |
| Realized investment gains (losses) | – | – | – | – | – | – | 3 | 0 | 0 | 0 |
| Research and development | 0 | – | – | – | 0 | 5 | 8 | 7 | 3 | 3 |
| Selling, general and administrative | 9 | 19 | 11 | 2 | 5 | 20 | – | – | – | – |
| Total operating expenses | 12 | 21 | 16 | 14 | – | – | – | – | – | – |
| Operating income | (5) | (11) | (7) | (2) | (6) | (65) | (27) | (16) | (10) | (9) |
| Interest expense | 1 | 1 | 1 | 0 | 0 | 0 | 0 | – | – | – |
| Other non-operating income (expense) | (1) | (1) | (3) | 0 | (1) | 8 | 7 | (1) | 0 | 0 |
| Income before taxes | (7) | (11) | (11) | (5) | (7) | (56) | (20) | (17) | (10) | (9) |
| Income tax expense | (4) | (2) | 6 | 0 | – | (7) | (1) | 0 | 0 | – |
| Net income from continuing operations | (3) | (9) | (17) | (6) | – | (49) | (18) | (17) | (10) | – |
| Net income | (3) | (9) | (17) | (2) | (7) | (49) | (18) | (17) | (10) | (9) |
| Net income to common shareholders | (3) | (11) | (19) | (6) | – | (49) | (19) | (17) | (10) | (12) |